Phase I trial in participants with rheumatoid arthritis and healthy volunteers with CIT-013, a first-in-class extracellular traps targeted therapy

EULAR Rheumatology Open 2026 Open access

Read full text
Authors: Micha N. Ronner, Naomi B. Klarenbeek, Salah Hadi, Leonie M. Middelink, Maarten C. Kraan
DOI: 10.1016/j.ero.2026.03.018
Cited by: 1
References: 5

Abstract

Aberrant extracellular trap (ET) formation and accumulation in tissue is associated with the pathophysiology of many inflammatory disorders, including rheumatoid arthritis (RA), as the enzymes and histones present in ETs are highly cytotoxic and proinflammatory [1].

Fields of Study & Subjects

Neutrophil Myeloperoxidase and Oxidative Mechanisms Extracellular vesicles in disease Cell Adhesion Molecules Research

Publication details

Journal / source
EULAR Rheumatology Open
Publisher
Elsevier BV
Volume
2
Issue
2
Pages
100170–100170
Publication date
1 May 2026
Language
EN